82 related articles for article (PubMed ID: 26277400)
1. GnRH-(1-5) activates matrix metallopeptidase-9 to release epidermal growth factor and promote cellular invasion.
Cho-Clark M; Larco DO; Zahn BR; Mani SK; Wu TJ
Mol Cell Endocrinol; 2015 Nov; 415():114-25. PubMed ID: 26277400
[TBL] [Abstract][Full Text] [Related]
2. GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor.
Cho-Clark M; Larco DO; Semsarzadeh NN; Vasta F; Mani SK; Wu TJ
Mol Endocrinol; 2014 Jan; 28(1):80-98. PubMed ID: 24264576
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9.
Cheung LW; Leung PC; Wong AS
Cancer Res; 2006 Nov; 66(22):10902-10. PubMed ID: 17108127
[TBL] [Abstract][Full Text] [Related]
4. The metabolite GnRH-(1-5) inhibits the migration of immortalized GnRH neurons.
Larco DO; Cho-Clark M; Mani SK; Wu TJ
Endocrinology; 2013 Feb; 154(2):783-95. PubMed ID: 23321696
[TBL] [Abstract][Full Text] [Related]
5. The role of GnRH metabolite, GnRH-(1-5), in endometrial cancer.
Cho-Clark MJ; Watkins A; Wu TJ
Front Endocrinol (Lausanne); 2023; 14():1183278. PubMed ID: 37124730
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxin III suppresses MDA-MB-231 cell metastasis through the inhibition of EGF/EGFR-mediated signaling pathway.
Tsai PC; Hsieh CY; Chiu CC; Wang CK; Chang LS; Lin SR
Toxicon; 2012 Oct; 60(5):734-43. PubMed ID: 22683533
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2.
Wu HM; Wang HS; Huang HY; Lai CH; Lee CL; Soong YK; Leung PC
BMC Cancer; 2013 Jun; 13():300. PubMed ID: 23786715
[TBL] [Abstract][Full Text] [Related]
8. Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Gründker C; Völker P; Emons G
Endocrinology; 2001 Jun; 142(6):2369-80. PubMed ID: 11356684
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells.
Ling Poon S; Lau MT; Hammond GL; Leung PC
Endocrinology; 2011 Mar; 152(3):764-72. PubMed ID: 21239435
[TBL] [Abstract][Full Text] [Related]
10. A novel epidermal growth factor receptor-signaling platform and its targeted translation in pancreatic cancer.
Gilmour AM; Abdulkhalek S; Cheng TS; Alghamdi F; Jayanth P; O'Shea LK; Geen O; Arvizu LA; Szewczuk MR
Cell Signal; 2013 Dec; 25(12):2587-603. PubMed ID: 23993964
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.
Ellerbroek SM; Halbleib JM; Benavidez M; Warmka JK; Wattenberg EV; Stack MS; Hudson LG
Cancer Res; 2001 Mar; 61(5):1855-61. PubMed ID: 11280738
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the motility of human decidual endometrial stromal cells: possible effect on embryo implantation and pregnancy.
Wu HM; Huang HY; Lee CL; Soong YK; Leung PC; Wang HS
Biol Reprod; 2015 Apr; 92(4):98. PubMed ID: 25761596
[TBL] [Abstract][Full Text] [Related]
13. Phenethyl isothiocyanate suppresses EGF-stimulated SAS human oral squamous carcinoma cell invasion by targeting EGF receptor signaling.
Chen HJ; Lin CM; Lee CY; Shih NC; Amagaya S; Lin YC; Yang JS
Int J Oncol; 2013 Aug; 43(2):629-37. PubMed ID: 23754208
[TBL] [Abstract][Full Text] [Related]
14. The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor.
Chatzaki E; Bax CM; Eidne KA; Anderson L; Grudzinskas JG; Gallagher CJ
Cancer Res; 1996 May; 56(9):2059-65. PubMed ID: 8616851
[TBL] [Abstract][Full Text] [Related]
15. Docosahexaenoic Acid Downregulates EGF-Induced Urokinase Plasminogen Activator and Matrix Metalloproteinase 9 Expression by Inactivating EGFR/ErbB2 Signaling in SK-BR3 Breast Cancer Cells.
Li CC; Yao HT; Cheng FJ; Hsieh YH; Lu CY; Wu CC; Liu KL; Chang JW
Nutr Cancer; 2015; 67(5):771-82. PubMed ID: 25970488
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
[TBL] [Abstract][Full Text] [Related]
17. GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells.
Eicke N; Günthert AR; Emons G; Gründker C
Int J Oncol; 2006 Nov; 29(5):1223-9. PubMed ID: 17016655
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
19. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.
Zuo JH; Zhu W; Li MY; Li XH; Yi H; Zeng GQ; Wan XX; He QY; Li JH; Qu JQ; Chen Y; Xiao ZQ
J Cell Biochem; 2011 Sep; 112(9):2508-17. PubMed ID: 21557297
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor (EGF) induces motility and upregulates MMP-9 and TIMP-1 in bovine trophoblast cells.
Dilly M; Hambruch N; Haeger JD; Pfarrer C
Mol Reprod Dev; 2010 Jul; 77(7):622-9. PubMed ID: 20578063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
